SPDL1 and myeloid sarcoma: Indeed, MS patients with a stable MRI image, defined as patients without new or contrast-enhancing lesions within 1 year prior to blood sampling, exhibited higher sPD-L1 levels as compared to patients with new or contrast-enhancing lesions (Fig. 4A, Table 2 and Supplementary Table 3).